Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates
© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists..
CYP3A is one of the most important classes of enzymes and is involved in the metabolism of over 70% drugs. While several selective CYP3A4 inhibitors have been identified, the search for a selective CYP3A5 inhibitor has turned out to be rather challenging. Recently, several selective CYP3A5 inhibitors have been identified through high-throughput screening of ~ 11,000 compounds and hit expansion using human recombinant enzymes. We set forth to characterize the three most selective CYP3A5 inhibitors in a more physiologically relevant system of human liver microsomes to understand if these inhibitors can be used for reaction phenotyping studies in drug discovery settings. Gomisin A and T-5 were used as selective substrate reactions for CYP3A4 and CYP3A5 to determine IC50 values of the two enzymes. The results showed that clobetasol propionate and loteprednol etabonate were potent and selective CYP3A5 reversible inhibitors with selectivity of 24-fold against CYP3A4 and 39-fold or more against the other major CYPs. The selectivity of difluprednate in HLM is much weaker than that in the recombinant enzymes due to hydrolysis of the acetate group in HLM. Based on the selectivity data, loteprednol etabonate can be utilized as an orthogonal approach, when experimental fraction metabolized of CYP3A5 is greater than 0.5, to understand CYP3A5 contribution to drug metabolism and its clinical significance. Future endeavors to identify even more selective CYP3A5 inhibitors are warranted to enable accurate determination of CYP3A5 contribution to metabolism versus CYP3A4.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The AAPS journal - 26(2024), 2 vom: 16. Feb., Seite 26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 09.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12248-024-00894-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368561313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368561313 | ||
| 003 | DE-627 | ||
| 005 | 20240410232527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240217s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12248-024-00894-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM368561313 | ||
| 035 | |a (NLM)38366061 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists. | ||
| 520 | |a CYP3A is one of the most important classes of enzymes and is involved in the metabolism of over 70% drugs. While several selective CYP3A4 inhibitors have been identified, the search for a selective CYP3A5 inhibitor has turned out to be rather challenging. Recently, several selective CYP3A5 inhibitors have been identified through high-throughput screening of ~ 11,000 compounds and hit expansion using human recombinant enzymes. We set forth to characterize the three most selective CYP3A5 inhibitors in a more physiologically relevant system of human liver microsomes to understand if these inhibitors can be used for reaction phenotyping studies in drug discovery settings. Gomisin A and T-5 were used as selective substrate reactions for CYP3A4 and CYP3A5 to determine IC50 values of the two enzymes. The results showed that clobetasol propionate and loteprednol etabonate were potent and selective CYP3A5 reversible inhibitors with selectivity of 24-fold against CYP3A4 and 39-fold or more against the other major CYPs. The selectivity of difluprednate in HLM is much weaker than that in the recombinant enzymes due to hydrolysis of the acetate group in HLM. Based on the selectivity data, loteprednol etabonate can be utilized as an orthogonal approach, when experimental fraction metabolized of CYP3A5 is greater than 0.5, to understand CYP3A5 contribution to drug metabolism and its clinical significance. Future endeavors to identify even more selective CYP3A5 inhibitors are warranted to enable accurate determination of CYP3A5 contribution to metabolism versus CYP3A4 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CYP3A4 | |
| 650 | 4 | |a CYP3A5 | |
| 650 | 4 | |a loteprednol etabonate | |
| 650 | 4 | |a reaction phenotyping | |
| 650 | 4 | |a selective inhibitor | |
| 650 | 7 | |a Cytochrome P-450 CYP3A Inhibitors |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Loteprednol Etabonate |2 NLM | |
| 650 | 7 | |a YEH1EZ96K6 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme System |2 NLM | |
| 650 | 7 | |a 9035-51-2 |2 NLM | |
| 650 | 7 | |a CYP3A5 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 700 | 1 | |a Tang, Lloyd Wei Tat |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Makayla |e verfasserin |4 aut | |
| 700 | 1 | |a Gualtieri, Gabrielle M |e verfasserin |4 aut | |
| 700 | 1 | |a DaSilva, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Danial |e verfasserin |4 aut | |
| 700 | 1 | |a Bora, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Che, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Di, Li |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The AAPS journal |d 2004 |g 26(2024), 2 vom: 16. Feb., Seite 26 |w (DE-627)NLM154144304 |x 1550-7416 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:2 |g day:16 |g month:02 |g pages:26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12248-024-00894-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 2 |b 16 |c 02 |h 26 | ||